-
Teva Announces Successful Results of Phase III Study of Its Long-Acting G-CSF Product in Breast Cancer Patients
Monday, June 6, 2011 - 9:21am | 102Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that lipegfilgrastim achieved its primary endpoint of reducing the duration of severe neutropenia in a Phase III study designed to evaluate the efficacy and safety of lipegfilgrastim compared to pegfilgrastim. Lipegfilgrastim, a...
-
Teva Announces Successful Results of Phase III Study of Its Long-Acting G-CSF Product in Breast Cancer Patients
Monday, June 6, 2011 - 9:21am | 102Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that lipegfilgrastim achieved its primary endpoint of reducing the duration of severe neutropenia in a Phase III study designed to evaluate the efficacy and safety of lipegfilgrastim compared to pegfilgrastim. Lipegfilgrastim, a...
-
UPDATE: Piper Jaffray Raises PT on Corcept Therapeutics to $7
Monday, June 6, 2011 - 8:46am | 129Piper Jaffray is out with its report today on Corcept Therapeutics (NASDAQ: CORT), raising its PT from $6 to $7. In a note to clients, Piper Jaffray writes, "Corcept presented Phase III data for Corlux, the company's lead drug for Cushing's Syndrome, at the ENDO meeting on Saturday. We expect...
-
UPDATE: Piper Jaffray Color on Akorn Initiation
Monday, June 6, 2011 - 7:42am | 188Piper Jaffray, which initiated coverage of Akorn (NASDAQ: AKRX), is providing some color on the stock. “We are initiating coverage of Akorn, Inc. with an Overweight rating and $10 price target,” Piper Jaffray writes. “Akorn's expanding generics portfolio, mainly focused on ophthalmics and...
-
J.P. Morgan Maintains Neutral on Bristol-Myers Squibb
Monday, June 6, 2011 - 7:35am | 146J.P. Morgan is out with its report today on Bristol-Myers Squibb (NYSE: BMY), maintaining Neutral. In a note to clients, J.P. Morgan writes, "Bristol presented first-line Yervoy data in the Plenary Session at ASCO yesterday. While the results gave us little reason to further increase our Yervoy...
-
Merck and ARIAD Announce Presentation of Results of Phase III SUCCEED Trial at American Society of Clinical Oncology Annual Meeting
Monday, June 6, 2011 - 7:31am | 196Merck (NYSE: MRK), known outside the United States and Canada as MSD, and ARIAD Pharmaceuticals, Inc., (NASDAQ: ARIA), today announced the presentation of detailed results from the Phase III SUCCEED clinical trial. SUCCEED evaluated oral ridaforolimus, an investigational mTOR inhibitor, in patients...
-
Piper Jaffray Reiterates Overweight on ViroPharma
Monday, June 6, 2011 - 7:11am | 150Piper Jaffray reiterated its Overweight rating on ViroPharma (NASDAQ: VPHM). In a research report published today, Piper stressed its concerns about generic competition for the company's Vancocin drug. At the same time, Piper expressed its belief that the company's shares buyback program might push...
-
Piper Jaffray Raises PT On Corcept Therapeutics To $7
Monday, June 6, 2011 - 7:02am | 27Piper Jaffray has raised the price target on Corcept Therapeutics (NASDAQ: CORT) from $6 to $7 and maintains its Overweight rating.
-
Piper Jaffray Initiates Akorn At Overweight, $10 PT
Monday, June 6, 2011 - 6:06am | 25Piper Jaffray has initiated coverage on Akorn, Inc. (NASDAQ: AKRX) with an Overweight rating and $10 price target.
-
Hepatitis C Virus (HCV) Updates from Biotech/Pharma Stocks
Friday, June 3, 2011 - 11:35am | 1743Point Roberts, WA - June 3, 2011 - Investorideas.com, a leader in sector stock issues a trading alert for biotech/pharma stocks Aethlon Medical, Inc. (OTCBB: AEMD), Vertex Pharmaceuticals Inc (VRTX). Merck & Company, Inc.(NYSE: MRK) following recent news and developments for the treatment of...
-
Forest Laboratories Announces Accelerated Share Repurchase
Friday, June 3, 2011 - 10:16am | 142Forest Laboratories (NYSE: FRX) announced today that it has entered into an agreement with Morgan Stanley & Co. Incorporated to repurchase $500 million of its common shares under an accelerated share repurchase program. Forest will acquire these common shares under the Board authorized 50...
-
Impax Laboratories Confirms Patent Suit Relating to Generic Detrol Immediate-Release 1 mg and 2 mg Tablets
Friday, June 3, 2011 - 9:16am | 121Impax Laboratories, Inc. (NASDAQ: IPXL) today confirms that Pfizer Inc. (NYSE: PFE), Pharmacia & Upjohn Company LLC and Pfizer Health AB have filed suit for patent infringement against Impax in the United States District Court for the District of New Jersey in connection with Detrol immediate-...
-
Ligand and Medicines Company Agree to Worldwide License for Proprietary Captisol®-Enabled Intravenous Formulation of Clopidogrel
Friday, June 3, 2011 - 9:06am | 160Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and The Medicines Company (NASDAQ: MDCO) announced today a licensing agreement under which Ligand has licensed exclusive worldwide rights to The Medicines Company for Ligand's Captisol®-enabled intravenous formulation of clopidogrel. Clopidogrel is...
-
UPDATE: J.P. Morgan Upgrades Forest Laboratories to Overweight
Friday, June 3, 2011 - 8:23am | 145J.P. Morgan is out with its report today on Forest Laboratories (NYSE: FRX), upgrading FRX from Neutral to Overweight. In a note to clients, J.P. Morgan writes, "We are upgrading FRX shares to Overweight from Neutral and see an increasingly favorable risk/reward profile for the stock. Our survey...
-
Benzinga's Top Pre-Market NASDAQ Losers
Friday, June 3, 2011 - 8:17am | 115Orexigen Therapeutics Inc (NASDAQ: OREX) dipped 26.73% to $2.33 in the pre-market session. Orexigen put the further development of its obesity drug candidate Contrave on hold. ARM Holdings plc (NASDAQ: ARMH) dropped 1.47% to $28.06 in the pre-market trading. ARMH's PEG ratio is 3.04. Randgold...